Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies

Journal of Hypertension

Volumn 30, Issue 5, 2012, Pages 1004-1014

  Verdecchia, Paolo ^a,b   Dagenais, Gilles ^c   Healey, Jeff ^b   Gao, Peggy ^b   Dans, Antonio L ^d   Chazova, Irina ^e   Binbrek, Azan S ^f   Iacobellis, Gianluca ^g   Ferreira, Rafael ^h   Holwerda, Nicolaas ⁱ   Karatzas, Nicholas ^j   Keltai, Matyas ^k   Mancia, Giuseppe ^l   Sleight, Peter ^m   Teo, Koon ^b   Yusuf, Salim ^b  

^a Assisi Hospital   (Italy)

^b MCMASTER UNIVERSITY   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d PHILIPPINE GENERAL HOSPITAL   (Philippines)

^e INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^f RASHID HOSPITAL   (United Arab Emirates)

^g MCMASTER UNIVERSITY   (Canada)

^h Praceta Do Comercio   (Portugal)

ⁱ Microvida Laboratory for Medical Microbiology and Immunology   (Netherlands)

^j HYGEIA HOSPITAL   (Greece)

^k SEMMELWEIS UNIVERSITY   (Hungary)

^l SAN GERARDO HOSPITAL   (Italy)

^m JOHN RADCLIFFE HOSPITAL   (United Kingdom)

more..

Author keywords

angiotensin receptor blockers; angiotensin converting enzyme inhibitors; atrial fibrillation; hypertension; left ventricular hypertrophy; obesity; ramipril; telmisartan

Indexed keywords

ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; RAMIPRIL; TELMISARTAN;

ADULT; ANTHROPOMETRY; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DEATH; FEMALE; FOLLOW UP; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; SINUS RHYTHM; STROKE; VASCULAR DISEASE;

EID: 84859885041     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283522a51     Document Type: Article

References (48)

1. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982; 306:1018-1022. (Pubitemid 12155370)
2. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995; 98:476-484.
3. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997; 96:2455-2461. (Pubitemid 27425856)
4. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98:946-952. (Pubitemid 28446646)
5. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82:2N-9N. (Pubitemid 28507114)
6. Wang TJ, Parise H, Levy D, D'Agostino RB Sr, Wolf PA, Vasan RS, Benjamin EJ. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004; 292:2471-2477. (Pubitemid 39552671)
7. Iacobellis G. Is obesity a risk factor for atrial fibrillation? Nat Clin Pract Cardiovasc Med 2005; 2:134-135. (Pubitemid 40823191)
8. Dublin S, French B, Glazer NL, Wiggins KL, Lumley T, Psaty BM, et al. Risk of new-onset atrial fibrillation in relation to body mass index. Arch Intern Med 2006; 166:2322-2328. (Pubitemid 44833356)
9. Mitchell GF, Vasan RS, Keyes MJ, Parise H, Wang TJ, Larson MG, et al. Pulse pressure and risk of new-onset atrial fibrillation. JAMA 2007; 297:709-715. (Pubitemid 46294560)
10. Verdecchia P, Reboldi G, Gattobigio R, Bentivoglio M, Borgioni C, Angeli F, et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension 2003; 41:218-223. (Pubitemid 36204892)
11. Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE, et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA 2006; 296:1242-1248. (Pubitemid 44394895)
12. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45:712-719. (Pubitemid 40282586)
13. Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45:705-711. (Pubitemid 40282585)
14. Pozzoli M, Cioffi G, Traversi E, Pinna GD, Cobelli F, Tavazzi L. Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol 1998; 32:197-204. (Pubitemid 28351062)
15. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559. (Pubitemid 351522739)
16. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372:1174-1183.
17. El Assaad M, Topouchian J, Le Dudal K, Labaki G, Asmar R. Validation of the Omron M5-I blood pressure device according to the international validation protocol. J Hypertens 2003; 21 (Suppl 4): S23.
18. Verdecchia P, Angeli F, Reboldi G, Carluccio E, Benemio G, Gattobigio R, et al. Improved cardiovascular risk stratification by a simple ECG index in hypertension. Am J Hypertens 2003; 16:646-652. (Pubitemid 36900587)
19. Verdecchia P, Sleight P, Mancia G, Fagard R, Trimarco B, Schmieder RE, et al. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. Circulation 2009; 120:1380-1389.
20. Landis JR, Koch GG. An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics 1977; 33:363-374. (Pubitemid 8131514)
21. Cox DR. Regression models and lifetables. J R Stat Soc 1972; 34:187-220.
22. Thomas MC, Dublin S, Kaplan RC, Glazer NL, Lumley T, Longstreth WT Jr, et al. Blood pressure control and risk of incident atrial fibrillation. Am J Hypertens 2008; 21:1111-1116.
23. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42:1206-1252. (Pubitemid 37553153)
24. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27:2121-2158.
25. Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001; 86:516-521. (Pubitemid 32999861)
26. Salehian O, Healey J, Stambler B, Alnemer K, Almerri K, Grover J, et al. Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study. Am Heart J 2007; 154:448-453. (Pubitemid 47271928)
27. Schneider MP, Hua TA, Bohm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 2010; 55:2299-2307.
28. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994; 271:840-844.
29. Tsang TS, Barnes ME, Miyasaka Y, Cha SS, Bailey KR, Verzosa GC, et al. Obesity as a risk factor for the progression of paroxysmal to permanent atrial fibrillation: a longitudinal cohort study of 21 years. Eur Heart J 2008; 29:2227-2233.
30. Tedrow UB, Conen D, Ridker PM, Cook NR, Koplan BA, Manson JE, et al. The long-and short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (women's health study). J Am Coll Cardiol 55:2319-2327.
31. Conen D, Tedrow UB, Cook NR, Buring JE, Albert CM. Birth weight is a significant risk factor for incident atrial fibrillation. Circulation 2010; 122:764-770.
32. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study. Lancet 2005; 366:1640-1649. (Pubitemid 41552419)
33. Dagenais GR, Yi Q, Mann JF, Bosch J, Pogue J, Yusuf S. Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J 2005; 149:54-60. (Pubitemid 40126490)
34. Snijder MB, Dekker JM, Visser M, Yudkin JS, Stehouwer CD, Bouter LM, et al. Larger thigh and hip circumferences are associated with better glucose tolerance: the Hoorn study. Obes Res 2003; 11:104-111. (Pubitemid 41137545)
35. Seidell JC, Han TS, Feskens EJ, Lean ME. Narrow hips and broad waist circumferences independently contribute to increased risk of noninsulin-dependent diabetes mellitus. J Intern Med 1997; 242:401-406. (Pubitemid 27513106)
36. Snijder MB, Zimmet PZ, Visser M, Dekker JM, Seidell JC, Shaw JE. Independent and opposite associations of waist and hip circumferences with diabetes, hypertension and dyslipidemia: the AusDiab Study. Int J Obes Relat Metab Disord 2004; 28:402-409. (Pubitemid 38296954)
37. Fruhbeck G. The adipose tissue as a source of vasoactive factors. Curr Med Chem Cardiovasc Hematol Agents 2004; 2:197-208. (Pubitemid 38864704)
38. Iacobellis G, Sharma AM. Obesity and the heart: redefinition of the relationship. Obes Rev 2007; 8:35-39. (Pubitemid 44952833)
39. Gami AS, Hodge DO, Herges RM, Olson EJ, NykodymJ, Kara T, Somers VK. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol 2007; 49:565-571. (Pubitemid 46177437)
40. Iguchi Y, Kimura K, Kobayashi K, Aoki J, Terasawa Y, Sakai K, et al. Relation of atrial fibrillation to glomerular filtration rate. Am J Cardiol 2008; 102:1056-1059.
41. Landray MJ, Wheeler DC, Lip GY, Newman DJ, Blann AD, McGlynn FJ, et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis 2004; 43:244-253. (Pubitemid 38146322)
42. Conen D, Tedrow UB, Koplan BA, Glynn RJ, Buring JE, Albert CM. Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. Circulation 2009; 119:2146-2152.
43. Novaro GM, Asher CR, Bhatt DL, Moliterno DJ, Harrington RA, Lincoff AM, et al. Meta-analysis comparing reported frequency of atrial fibrillation after acute coronary syndromes in Asians versus whites. Am J Cardiol 2008; 101:506-509. (Pubitemid 351199442)
44. Borzecki AM, Bridgers DK, Liebschutz JM, Kader B, Kazis LE, Berlowitz DR. Racial differences in the prevalence of atrial fibrillation among males. J Natl Med Assoc 2008; 100:237-245. (Pubitemid 351281177)
45. Djousse L, Levy D, Benjamin EJ, Blease SJ, Russ A, Larson MG, et al. Long-term alcohol consumption and the risk of atrial fibrillation in the Framingham Study. Am J Cardiol 2004; 93:710-713. (Pubitemid 38338559)
46. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-1151.
47. Schmieder RE, Kjeldsen SE, Julius S, McInnes GT, Zanchetti A, Hua TA. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens 2008; 26:403-411. (Pubitemid 351317247)
48. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347:969-974.